Aarti Pharmalabs Limited declared a final dividend of ₹2 per equity share of face value ₹5 each for the financial year ended March 31, 2026, during its 7th Annual General Meeting held on September 22, 2026.

The meeting, conducted via Video Conferencing/Other Audio Visual Means, also approved significant changes to the company's leadership structure effective October 1, 2026. These resolutions mark a shift in the executive roles within the Gogri family leadership team.

Leadership restructuring approved

Shareholders passed special resolutions to alter the designations of key board members. Rashesh C. Gogri was appointed as Managing Director, transitioning from his previous role as Non-Executive Director. Concurrently, Hetal Gogri Gala was re-designated from Managing Director to Whole-time Director.

Additionally, Rajendra Gogri, who was liable to retire by rotation, did not offer himself for re-appointment. The shareholders resolved that the vacancy created on the Board would not be filled.

Financial statements adopted

The audited standalone and consolidated financial statements for FY26 were adopted without any qualifications or comments in the Statutory and Secretarial Auditor reports. The Board also ratified the remuneration payable to Cost Auditors for the financial year ending March 31, 2027.

Voting and compliance details

The company facilitated remote e-voting for all resolutions, with the voting period running from September 19, 2026, to September 21, 2026. The results of the e-voting will be declared within two working days of the meeting's conclusion and posted on the company website and stock exchange platforms.

Aarti Pharma Labs shares worth ₹62.93 crore were flagged by a real-time large-trade signal on the NSE, with approximately 765,697 shares changing hands at ₹821.9 per share.

This is a real-time large-trade signal, not a confirmed block or bulk deal. NSE/BSE publish official block and bulk deal reports only after market close — this trade may or may not appear there.

Trade details

The following table summarises the key parameters of the flagged activity:

The signal reflects a cluster of trades in Aarti Pharma Labs printed within a short window at or near ₹821.9, for a combined value of ₹62.93 crore. This activity was flagged by a real-time trade-scanning system based on size and speed of execution, and has not been confirmed by the exchange as an officially reported event.

No buyer, seller, broker, or client identity is available at this stage. Such information, if applicable, would only be disclosed by the exchange after market close through its own reporting mechanism.

What this signal is, and isn't

What this is, and isn't: this reflects trade-level activity — a cluster of trades in the stock above, printed within a short window at or near the quoted price, for a combined value as stated. It is generated by our real-time trade-scanning system and is not, by itself, evidence of a block or bulk deal.

A block deal has to be executed in the exchange's dedicated window (8:45–9:00am or 2:05–2:20pm), within a set price band, and above the current minimum order size (₹25 crore). A bulk deal is when one client's total trading in a stock crosses 0.5% of its equity in a single day — confirmed only once every trade that client made is added up.

Both are published by NSE/BSE after trading hours end, typically after 3:30pm — never before. If this trade qualifies as either, it will appear in the exchange's own report later today, not here first.